论文部分内容阅读
目的 :探讨 Ph染色体阳性的急性白血病 (Ph+ AL )患者免疫表型及临床特征。方法 :对 19例初诊为Ph+ AL 患者进行细胞形态学、细胞遗传学及免疫表型检测 ,结合患者白细胞数、感染情况及临床治疗的疗效和生存期进行综合分析。结果 :Ph+ 急性淋巴细胞白血病 (AL L ) 9例 ,占同期 AL L患者的 33.3% ,免疫表型以 CD1 0 - 的B细胞系 AL L 占 83.3% ,年龄≤ 30岁者占 88.9% ,完全缓解率为 6 6 .7% ,平均生存期 <1年。Ph+急性髓细胞性白血病 (AML) 10例 ,占同期 AML 患者的 9.3% ,免疫表型伴淋系表达率高 (占 5 0 % ) ,FAB分型以 M4多见 ,年龄 >5 0岁者占 5 0 % ,完全缓解率为 30 %。结论 :Ph+ AL 在免疫表型、临床特征及形态学方面存在其特殊性 ,其生存期短 ,疗效差。
Objective: To investigate the immunophenotype and clinical features of Ph chromosome-positive acute leukemia (Ph+ AL) patients. Methods : 19 patients with newly diagnosed Ph+ AL were examined for cytomorphology, cytogenetics, and immunophenotyping. A comprehensive analysis of WBC count, infection status, clinical efficacy, and survival time was performed. Results: Ph+ acute lymphoblastic leukemia (AL L) in 9 cases, accounting for 33.3% of patients with AL L in the same period, immunophenotype in CD1 0 - B cell line AL L accounted for 83.3%, age ≤ 30 years accounted for 88.9%, completely The response rate was 66.7% and the average survival period was <1 year. Ph+ acute myelogenous leukemia (AML) 10 cases, accounting for 9.3% of AML patients in the same period, immunophenotype associated with high expression rate of leptomery line (50%), FAB type is more common with M4, age> 50 years old It accounts for 50% and complete remission rate is 30%. Conclusion : Ph+ AL has its specificity in immunophenotype, clinical features and morphology. Its survival time is short and its efficacy is poor.